Jiangsu Pacific Meinuoke Biopharmaceuticals
Focus: Jiangsu Pacific Meinuoke is a China-based biopharmaceutical company specializing in monoclonal antibodies and CAR-T cell therapies with focus on neurology and cell therapy indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Jiangsu Pacific Meinuoke Biopharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Jiangsu Pacific Meinuoke Biopharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Declining
Post-LOE
Generic/ANDA product in mature, competitive ophthalmology market generating minimal strategic value.
Products & Portfolio (1)
Help build intelligence for Jiangsu Pacific Meinuoke Biopharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.